MedTrace Logo

Targeting Metabolic Flexibility in Amyotrophic Lateral Sclerosis (ALS)

NCT04788745 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2023-07-20

No results posted yet for this study

Summary

MetFlex is an investigator led, open-label, single-arm, Phase 2a trial to determine the safety and tolerability of trimetazidine for the treatment of amyotrophic lateral sclerosis/motor neuron disease (ALS/MND).

Conditions

Interventions

DRUG

Trimetazidine Dihydrochloride

Oral tablet, twice-daily

Sponsors & Collaborators

  • FightMND

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • Julius Clinical

    collaborator INDUSTRY

  • The University of Queensland

    lead OTHER

Principal Investigators

  • Shyuan Ngo, PhD · The University of Queensland

  • Robert Henderson, MBBS, PhD · Royal Brisbane & Women's Hospital

  • Leonard van den Berg, MD, PhD · UMC Utrecht

  • Ammar Al-Chalabi, MB ChB, PhD · King's College London

  • Frederik Steyn, PhD · The University of Queensland

  • Ruben van Eijk, MD, PhD · UMC Utrecht

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2023-05-24
Completion
2023-05-24

Countries

  • Australia
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04788745 on ClinicalTrials.gov